Methods, evidence and limits
How SentinelDose reaches a finding, what it rests on, and what it does not do. Rule set version 1.0.0.
Two layers
Rule engine. A deterministic engine written in TypeScript runs in your browser. It recognizes 545 medicines and 97 foods, supplements, substances and situations. Each carries curated properties: metabolic pathways, enzyme inhibition and induction strength, QT liability, anticholinergic burden score, and graded effects on bleeding, potassium, blood pressure, sedation and more. From these it computes cumulative burdens and pharmacokinetic interactions, and it applies 77 individually written interaction rules and 17 prescribing-cascade patterns. The same input always gives the same output.
AI synthesis (Pro, optional). A language model receives the de-identified case with the rule findings. It re-ranks them for the individual patient, adds short notes, comments on entries the rules did not recognize, and may add concerns. Anything the model adds is labeled “AI-added, verify” and carries lookup links only, because the model is not permitted to supply its own citations.
Drugs outside the curated list
When a name is not in the curated list, the app can look it up in RxNorm, the drug-name database of the US National Library of Medicine. A brand is resolved to its ingredients. An ingredient that is not curated is placed in its WHO ATC drug class and receives that class's rules only, and every finding that depends on it is graded no higher than “probable” and says so.
The FDA label cross-check then fetches the current FDA-approved label for each medicine from openFDA and searches its interaction, contraindication and boxed-warning sections for the other items on the list. Matches are shown as quotations with a link to the full label. They are not rated, and a mention can also state that no interaction exists.
Evidence strength on every finding
- Established. Supported by regulatory labeling, a clinical guideline or controlled studies.
- Probable. Consistent pharmacology with observational data, case series or expert consensus.
- Theoretical. Based on mechanism. Clinical evidence is limited or conflicting, and the finding says so.
Each finding links to its sources. Links marked “Look up” are searches of FDA labeling (DailyMed) and PubMed for the agents involved, offered so you can check the current wording yourself. Every reference in the list below was checked to resolve to the named document when this version was built.
Privacy
Rule-based reviews are computed in the browser. The optional NIH and FDA lookups send drug names, and nothing else, straight from your browser to those agencies; they can be switched off under the Analyze button. Our server receives only counts and rule identifiers, so that the accuracy dashboard can show which rules fire and how they are rated. Feedback sends the rule identifier and the drug names in that finding. AI synthesis sends the de-identified case (age, sex, weight, labs, conditions and the lists you typed) to the model provider and stores nothing. Do not enter names, dates of birth or record numbers. Use with identifiable patient data requires your organization's own privacy and security review.
Limits
- The rule set is curated, not exhaustive. Absence of a finding is not evidence of safety.
- It has not been clinically validated in a prospective study and is not a cleared medical device.
- Coverage is thin for oncology, antiretroviral, pediatric and specialty medicines. Pregnancy and lactation are not assessed.
- It does not check indication, dose adequacy, allergies, pharmacogenomics or missing therapy.
- Renal thresholds paraphrase labeling and prompt a dose check; they do not replace it.
- Perioperative guidance follows the cited guidelines; local protocols and the surgical and anesthesia teams take precedence.
- Guidelines change. Each rule cites the version it was written against.
References (55)
Guidelines
- 2023 AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults
- STOPP/START criteria version 3 (2023)
- KDIGO 2024 Clinical Practice Guideline for CKD
- CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Pain
- 2020 ACC Expert Consensus Decision Pathway: anticoagulant and antiplatelet therapy in AF or VTE with PCI or ASCVD
- ATA 2014 guidelines for the treatment of hypothyroidism
- IDF-DAR 2021 practical guidelines: diabetes and Ramadan
- CDC ACIP: vaccination with altered immunocompetence
- ACR Manual on Contrast Media
- ACCP 2022: perioperative management of antithrombotic therapy (CHEST)
- 2024 AHA/ACC guideline for perioperative cardiovascular management for noncardiac surgery
- 2022 ACR/AAHKS guideline: perioperative antirheumatic medication in joint arthroplasty
- ADA Standards of Care 2025, section 16: diabetes care in the hospital
- 2024 multisociety guidance: GLP-1 receptor agonists in the perioperative period
- ASA 2023 consensus guidance: preoperative GLP-1 receptor agonists
- ASRA 2023 guidelines: perioperative management of cannabis and cannabinoids
- ASRA 2018: regional anesthesia in patients receiving antithrombotic therapy, 4th edition
Regulators
- FDA: Table of Substrates, Inhibitors and Inducers
- FDA 2020: boxed warning update for the benzodiazepine class (includes opioid co-use)
- FDA: serious breathing problems with gabapentin and pregabalin
- FDA: Grapefruit juice and some drugs don't mix
- FDA: Some medicines and driving don't mix
- FDA: The sun and your medicine
- FDA and kratom
Trials and cohort studies
- Inker 2021: CKD-EPI creatinine equation without race
- Lapi 2013: diuretics, ACE inhibitors or ARBs with NSAIDs and AKI risk (BMJ)
- Juurlink 2004: hyperkalemia after publication of RALES (NEJM)
- Antoniou 2011: trimethoprim-sulfamethoxazole with spironolactone and hyperkalemia (BMJ)
- ONTARGET 2008: telmisartan, ramipril or both (NEJM)
- Savage 2020: calcium channel blocker to loop diuretic prescribing cascade (JAMA Intern Med)
- PAUSE 2019: perioperative DOAC interruption without bridging (JAMA Intern Med)
- BRIDGE 2015: perioperative bridging anticoagulation in atrial fibrillation (NEJM)
- Stop-or-Not 2024: continuing vs stopping RAS inhibitors before major noncardiac surgery (JAMA)
Reviews
Reference databases
- Flockhart Table: Cytochrome P450 Drug Interactions (Indiana University)
- CredibleMeds: QTdrugs lists
- Cockcroft and Gault 1976: prediction of creatinine clearance
- NIH LiverTox: drug-induced liver injury database
- NIH Office of Dietary Supplements: Vitamin K fact sheet
- NIH Office of Dietary Supplements: Potassium fact sheet
- NIH Office of Dietary Supplements: Calcium fact sheet
- NIH Office of Dietary Supplements: Iron fact sheet
- NIH Office of Dietary Supplements: Biotin fact sheet
- NCCIH: Herb-drug interactions (clinical digest)
- NCCIH: St. John's wort
- NCCIH: Licorice root
- NCCIH: Kava
- NCCIH: Ginkgo
- NCCIH: Red yeast rice
- NCCIH: Cannabis (marijuana) and cannabinoids
- NIAAA: Harmful interactions, mixing alcohol with medicines
- CDC: Heat and medications, guidance for clinicians